Previous studies have reported that HER2‐positive breast cancers harboring PIK3CA mutations may exhibit reduced sensitivity to trastuzumab, pertuzumab, and lapatinib [31, 32, 33, 34]. Here, ERBB2 is linked to breast cancer.